 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE:ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma GEA pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers. HERIZON-GEA-01 is a randomized, global Phase 3 